CTIS2023-510076-31-00进行中（未招募）1 期
A single center, single arm, Phase 2, pilot study to investigate the efficacy of an angiotensin-converting enzyme inhibitor (ACE-inhibitor) in male and female participants aged 18-70 years of age with painful venous malformations.
Oslo University Hospital HF0 个研究点目标入组 1 人开始时间: 2024年2月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients with venous malformations verified by clinical examination, ultrasound and anatomic MRI with contrast. The venous malformation should have well defined borders and the volume should be measurable on MRI. Diagnosis of venous malformation shall be object for consensus in a multidisciplinary team meeting., Patients must experience pain from the malformation. Pain is defined as local pain in the malformation, and the participant must have pain that according to the patient inhibits daily activity, interferes with sleep and reduces quality of life. NRS inclusion criteria is greater or equal to 4., Participant must be 18 to 70 years of age inclusive, at the time of signing the informed consent., Negative urine pregnancy test in females with childbearing potential. A woman is considered of childbearing potential i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy., Woman of childbearing potential (WOCBP) must use highly effective contraception measures while on study medicine and for up to 2 weeks past treatment. Highly effective birth control methods include: ?Combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation. ?Progestogen-only hormonal contraception associated with inhibition of ovulation ?Intrauterine device (IUS) ?Intrauterine hormone-releasing system (IUS) ?Bilateral tubal occlusion ?Vasectomized partner ?Sexual abstinence (controlled with regular questioning by PI), Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). They must also be capable of answer adequately questionnaires regarding quality of life. Since the questionnaire are validated in Norwegian and English, they also should control one of this language.
排除标准
- •Diffuse VM with no defined borders., Use of mTOR-inhibitor, racekadotril, sacubitril/valsartan, ramipril or vildagliptin is contraindicated because of an elevated risk of angioedema, Use of angiotensin-II receptor antagonist or alsikiren (direct renin inhibitor) is contraindicated because of increased risk of hypotension, hyperkalemia, and impaired renal function., Impaired cardiac function and clinically significant cardiac disease including aorta- and mitral valve stenosis and hypertrophic cardiomyopathy., Lactose intolerance, total lactase deficiency or glucose-galactose malabsorption because Enalapril contains lactose., Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the ACE-inhibitor (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea > grade 2, malabsorption syndrome, or small bowel resection.), Hypersensitivity to the active substance or any of the excipients listed in section 6.1 of the SmPC of the SmPC of enalpril or to other ACE-inhibitors., Patients with a history of angioneurotic edema related to previous treatment with ACE-inhibitors and patients with Hereditary or ideopatic anigioneurotic edema, Patient has other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, contraindicated participation in the clinical study, Known renal artery stenosis, BMI > 30, Impaired renal function (eGFR < 50 ml/min/1,73m2), Pregnant or lactating woman, Any condition that in the view of the investigator would suggest that the patient is unable to comply with the study protocol and procedures., Known diabetes because of the risk of hypoglycemia., Chronic liver failure
研究者
相似试验
尚未招募
2 期
A phase II, open, single arm, single center study to evaluate the efficacy and safety of compound Huangdai tablets for advanced liver cancerprimary liver cancerITMCTR2100005192Changhai Hospital, Navy Military Medical University, Shanghai
进行中（未招募）
不适用
Pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day.active bullous pemphigoidMedDRA version: 14.0Level: LLTClassification code 10006567Term: Bullous pemphigoidSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-000756-42-DEDompé s.p.a.12
进行中（未招募）
不适用
pilot phase 2 clinical trial performed in some hospitals to evaluate the efficacy and the adverse events in a group of patients with active bullous pemphigoid that will receive DF2156A at the dose of 150 mg, oral route, twice a day.active bullous pemphigoidMedDRA version: 14.1Level: LLTClassification code 10006567Term: Bullous pemphigoidSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-000756-42-ITDOMPE' s.p.a.12
已完成
2 期
The Hunter Humira and Endothelial Function in Early Rheumatoid Arthritis TrialMusculoskeletal - Other muscular and skeletal disordersCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemInflammatory and Immune System - Rheumatoid arthritisCardiovascular DiseaseRheumatoid ArthritisACTRN12611000972921A/Prof Stephen Oakley60
已完成
2 期
An open, single center, single-arm phase II study to evaluate the safety of a modificated perioperative analgesia with Indometacin during pancreaticoduodenectomyMedDRA - 10045751 (Unspecified disease of pancreas)DRKS00011321niversitätsklinikum Freiburg58